Literature DB >> 8411739

Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group.

K Tobinai, A Kohno, Y Shimada, T Watanabe, T Tamura, K Takeyama, M Narabayashi, T Fukutomi, H Kondo, M Shimoyama.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8411739

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN： 0368-2811            Impact factor:   3.019


× No keyword cloud information.
  41 in total

1.  Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508.

Authors:  Yoshitoyo Kagami; Kuniaki Itoh; Kensei Tobinai; Haruhiko Fukuda; Kiyoshi Mukai; Takaaki Chou; Chikara Mikuni; Tomohiro Kinoshita; Noriyasu Fukushima; Yoshio Kiyama; Takayo Suzuki; Tsuneo Sasaki; Yuko Watanabe; Kunihiro Tsukasaki; Tomomitsu Hotta; Masanori Shimoyama; Michinori Ogura
Journal:  Int J Hematol       Date:  2012-06-03       Impact factor: 2.490

2.  Conventional Dose CAF Therapy versus Low Dose Adriamycin Therapy in the Treatment of Advanced Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1994-07-30       Impact factor: 4.239

3.  CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer.

Authors: 
Journal:  Breast Cancer       Date:  1995-04-30       Impact factor: 4.239

4.  Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).

Authors:  Michinori Ogura; Kuniaki Itoh; Tomohiro Kinoshita; Haruhiko Fukuda; Takeaki Takenaka; Tomoko Ohtsu; Yoshitoyo Kagami; Kensei Tobinai; Masataka Okamoto; Hideki Asaoku; Tsuneo Sasaki; Chikara Mikuni; Masami Hirano; Takaaki Chou; Kazunori Ohnishi; Hitoshi Ohno; Kaori Nasu; Kenichi Okabe; Shuichi Ikeda; Shigeo Nakamura; Tomomitsu Hotta; Masanori Shimoyama
Journal:  Int J Hematol       Date:  2010-11-16       Impact factor: 2.490

5.  Phase II clinical study of cladribine in the treatment of hairy cell leukemia.

Authors:  Takashi Machii; Takaaki Chou; Muneou Suzuki; Yokiko Ohe; Shuichi Katagiri; E Kiyoshi Kitano; Kiyoshi Kitano; Yoshihide Fujiyama; Tooru Izumi; Chihiro Shimazaki; Koji Nanba; Yasuo Ohashi; Teruo Kitani
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

6.  Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors:  Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

7.  Replacement of cisplatin with nedaplatin in a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Authors:  Akiko Kuwahara; Motohiro Yamamori; Kohshi Nishiguchi; Tatsuya Okuno; Naoko Chayahara; Ikuya Miki; Takao Tamura; Tsubasa Inokuma; Yoshiji Takemoto; Tsutomu Nakamura; Kazusaburo Kataoka; Toshiyuki Sakaeda
Journal:  Int J Med Sci       Date:  2009-09-28       Impact factor: 3.738

8.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

9.  A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605).

Authors:  H Kunitoh; T Tamura; T Shibata; K Nakagawa; K Takeda; Y Nishiwaki; Y Osaki; K Noda; A Yokoyama; N Saijo
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

10.  Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer.

Authors:  H Tsuda; Y Hashiguchi; S Nishimura; M Miyama; S Nakata; N Kawamura; S Negoro
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.